Blog
RSS FeedPosted by Michael Wonder on 13 Jan 2025
International collaboration provides new guidance on the use of surrogate endpoints in cost effectiveness analysis
9 January 2025 - Recommendations will help organisations that appraise new drugs establish whether their use will result in longer-term ...
Posted by Michael Wonder on 27 Dec 2024
Alnylam Canada signs letter of intent from pan-Canadian Pharmaceutical Alliance for the public reimbursement of Amvuttra for the treatment of hereditary transthyretin-mediated amyloidosis in adults
18 October 2024 - One step closer to achieving public reimbursement of Amvuttra for hereditary transthyretin-mediated amyloidosis. patients in Canada ...
Posted by Michael Wonder on 06 Dec 2024
Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases
5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...
Posted by Michael Wonder on 05 Dec 2024
Canada’s Drug Agency launches consultation on methods guide
28 November 2024 - Canada’s Drug Agency is launching a consultation on its first ever methods guide. ...
Posted by Michael Wonder on 27 Nov 2024
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)
19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...
Posted by Michael Wonder on 09 Nov 2024
Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement
8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...
Posted by Michael Wonder on 04 Nov 2024
NS parents dismayed by lack of access to new RSV vaccines for infants
3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...
Posted by Michael Wonder on 01 Nov 2024
Differences in drug shortages in the US and Canada
31 October 2024 - In this cross-sectional study, there were 104 reports of drug-related supply chain issues that occurred from 2017 ...
Posted by Michael Wonder on 24 Oct 2024
Canada’s Drug Agency announces recipients of funding to enhance rare disease registries
21 October 2024 - Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) ...
Posted by Michael Wonder on 18 Oct 2024
Government of Canada announces new appointment to the Patented Medicine Prices Review Board
17 October 2024 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine ...
Posted by Michael Wonder on 07 Oct 2024
New flexible service through our scientific advice program
26 September 2024 - Drug sponsors can now request a flexible service through our scientific advice program that can include ...
Posted by Michael Wonder on 21 Sep 2024
New COVID-19 vaccine by Moderna approved by Health Canada
17 September 2024 - Health Canada has approved an updated version of Moderna’s COVID-19 vaccine, a decision that means some ...
Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...
Posted by Michael Wonder on 20 Sep 2024
Abrysvo: Pfizer Canada's newly publicly funded vaccine a step towards national RSV prevention in older adults
19 September 2024 - Today, Pfizer Canada announced that Abrysvo has been selected as the publicly funded vaccine for the ...
Posted by Michael Wonder on 05 Sep 2024
Today’s the day: we are officially Canada’s Drug Agency
5 September 2024 - We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical ...